Analysts are on the Bearish side about ResMed Inc. (NYSE:RMD) this week.

June 19, 2017 - By Darrin Black

 Analysts are on the Bearish side about ResMed Inc. (NYSE:RMD) this week.
Investors sentiment decreased to 0.99 in Q4 2016. Its down 0.10, from 1.09 in 2016Q3. It turned negative, as 39 investors sold ResMed Inc. shares while 117 reduced holdings. 35 funds opened positions while 120 raised stakes. 85.86 million shares or 1.89% less from 87.52 million shares in 2016Q3 were reported.
Orrstown Ser holds 65 shares or 0% of its portfolio. Janney Montgomery Scott Lc invested 0.01% of its portfolio in ResMed Inc. (NYSE:RMD). 215,696 were accumulated by Investment Ser Of America. Winfield Assoc Inc invested 0% in ResMed Inc. (NYSE:RMD). Washington Tru Bank accumulated 12 shares. Thompson Mngmt Incorporated owns 50,772 shares. 22,900 were reported by Andra Ap. Kbc Gru Nv has invested 0.02% in ResMed Inc. (NYSE:RMD). Moreover, State Board Of Administration Of Florida Retirement has 0.04% invested in ResMed Inc. (NYSE:RMD) for 224,049 shares. Fincl Architects holds 0.07% or 4,550 shares in its portfolio. 111,954 were accumulated by Alliancebernstein Lp. Macquarie Grp Ltd has invested 0.03% in ResMed Inc. (NYSE:RMD). Apg Asset Management Nv holds 0.05% or 436,900 shares in its portfolio. Balyasny Asset Mgmt Ltd Liability holds 0.08% of its portfolio in ResMed Inc. (NYSE:RMD) for 247,969 shares. Pillar Pacific Mgmt Limited Liability reported 38,120 shares stake.

Since January 3, 2017, it had 0 insider buys, and 20 selling transactions for $15.39 million activity. ROBERTS CHRISTOPHER G sold 10,000 shares worth $719,100. Shares for $1.43M were sold by FARRELL PETER C on Monday, March 6. Another trade for 1,250 shares valued at $85,750 was sold by Sandercock Brett. Shares for $394,312 were sold by PENDARVIS DAVID. Shares for $456,493 were sold by Hollingshead James on Tuesday, January 17. The insider PACE GARY W sold 24,390 shares worth $1.85 million.

ResMed Inc. (NYSE:RMD) Ratings Coverage

Among 13 analysts covering ResMed Inc (NYSE:RMD), 4 have Buy rating, 3 Sell and 6 Hold. Therefore 31% are positive. ResMed Inc has $66 highest and $52 lowest target. $59.14’s average target is -23.29% below currents $77.1 stock price. ResMed Inc had 23 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Neutral” rating by JP Morgan given on Friday, April 21. The firm has “Underperform” rating given on Monday, June 27 by Needham. The firm earned “Neutral” rating on Wednesday, April 27 by Piper Jaffray. The rating was downgraded by JP Morgan to “Neutral” on Monday, September 19. The rating was downgraded by Barclays Capital on Tuesday, January 19 to “Underweight”. The firm earned “Hold” rating on Thursday, December 17 by Needham. The company was upgraded on Friday, January 22 by Credit Suisse. As per Tuesday, January 24, the company rating was maintained by Canaccord Genuity. As per Thursday, September 29, the company rating was upgraded by Bank of America. Barclays Capital initiated ResMed Inc. (NYSE:RMD) rating on Thursday, April 7. Barclays Capital has “Underweight” rating and $55 target. Below is a list of ResMed Inc. (NYSE:RMD) latest ratings and price target changes.

02/06/2017 Broker: Jefferies Rating: Sell New Target: $56.0000 Maintain
15/05/2017 Broker: BMO Capital Markets Rating: Hold Maintain
28/04/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade
21/04/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade
24/01/2017 Broker: Canaccord Genuity Rating: Hold Old Target: $55 New Target: $59 Maintain
24/01/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade

It closed at $77.1 lastly. It is down 20.34% since June 19, 2016 and is uptrending. It has outperformed by 3.64% the S&P500.

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing , chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. The company has market cap of $11.07 billion. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. It has a 32.86 P/E ratio. The Company’s cloud software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes.

Another recent and important ResMed Inc. (NYSE:RMD) news was published by Zacks.com which published an article titled: “Why Is ResMed (RMD) Down 3.8% Since the Last Earnings Report?” on May 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.